Showing 19 results
Archival DescriptionCost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
MS cost-effectiveness study correspondence and meeting notes
MS cost-effectiveness study correspondence and meeting notes
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Analysis of physician location and relocation decisions in Nova Scotia data programming codebook
Analysis of physician location and relocation decisions in Nova Scotia data programming codebook
Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness
Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Dalhousie MS Research Group meeting minutes
Dalhousie MS Research Group meeting minutes
National Multiple Sclerosis Society (NMSS) COSTRIMS study
National Multiple Sclerosis Society (NMSS) COSTRIMS study
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
Multiple sclerosis net benefits feasibility study
Multiple sclerosis net benefits feasibility study
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data